Hair loss can be one of the most difficult aspects of chemotherapy, particularly for women.
Some women who take Taxotere®, a drug used in the majority of breast cancer treatments, are left with permanent hair loss. In December 2015, the FDA required the warning label be changed to include a risk of alopecia, permanent hair loss.
Women who took the drug before the label change were not sufficiently warned of the potential for permanent hair loss. Internal studies demonstrate that the manufacturer knew, but failed to disclose, that 9 percent of women who take the drug will suffer from alopecia. Had they warned women, many would have likely taken the alternative drug, Taxol®, which does not have that side effect.
We are pursuing cases against Sanofi-Aventis for failing to disclose this important side effect and are seeking women who took the drug prior to the label change in December 2015. Please contact us to set up a free case review.
How we can help
RPWB represents people throughout the country who were injured as a result of pharmaceutical drugs, medical devices and other unsafe products. Our firm is well-known for its powerful role on behalf of consumers who rely on pharmaceutical companies for safe and effective treatments. We have been appointed lead counsel in seven large multi-district litigations and leadership positions in many more. Our attorneys are sensitive to the wishes of our clients yet tenacious and experienced enough to secure the compensation our clients need and deserve.
Please contact us to set up a free, no obligation case evaluation and to learn about your legal options.